Skip to search formSkip to main contentSkip to account menu

AH-5158

Known as: AH 5158, AH5158 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Labetalol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1980
1980
ON THE SUBACUTE TOXICITY OF LABETALOL (AH5158) : A COMBINED α-AND β-ADRENOCEPTOR-BLOCKING AGENT
Subacute toxicity and recovery tests of labetalol hydrochloride, α-and β-adrenoceptor blocking agent, were carried out using male… 
1980
1980
[On the subacute toxicity of labetalol (AH5158): a combined alpha-and beta-adrenoceptor blocking agent (author's transl)].
Subacute toxicity and recovery tests of labetalol hydrochloride, alpha- and beta-adrenoceptor blocking agent, were carried out… 
1980
1980
[On the chronic toxicity of labetalol (AH-5158); a combined alpha-and beta-adrenoceptor-blocking agent (author's transl)].
Chronic toxicity and recovery tests of labetalol hydrochloride, alpha-and beta-adrenoceptor blocking agent, were carried out… 
1978
1978
[On the acute toxicity of labetalol (AH-5158), a combined alpha-and-beta-adrenoceptor-blocking agent (author's transl)].
Acute toxicity studies in labetalol were performed using mice, rats and rabbits, An oral administration of labetalol produced an… 
1976
1976
Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.
Labetalol (AH5158) a new alpha- and beta-adrenergic blocking agent was given to 12 hypertensive patients for an average of 7… 
1976
1976
Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo.
1. Labetalol (AH 5158) is a new drug which has both alpha- and beta-adrenoreceptor antagonist activity. Labetalol has been… 
1976
1976
The effects of AH 5158 on metabolism of 3H(-)noradrenaline released from the cat spleen by nerve stimulation [proceedings].
1975
1975
Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals.
1. AH 5158, 5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)salicylamide, competitively antagonised phenylephrine-induced… 
1974
1974
The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers.
1 In healthy male volunteers after single oral doses, AH 5158 produced inhibition of exercise induced tachycardia, falls in… 
1973
1973
The effects of a new alpha- and beta-adrenoceptor antagonist (AH5158) upon the general and coronary haemodynamics of intact dogs.
AH5158, a salicylamide derivative, said to be a blocker of alpha- and beta-adrenoceptors, has been studied in intact… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)